Does Rivaroxaban Have a Role in Treating Patients with PAD?

Authors

Rebekah Thomas, Philadelphia College of Osteopathic MedicineFollow

Document Type

Article

Publication Date

7-1-2019

Abstract

Peripheral arterial disease can cause devastating health outcomes, and few therapies are available to treat this condition. Results of a secondary analysis of the COMPASS trial suggest benefit with the use of rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily. This treatment regimen could change the standard pharmacotherapeutic management practice for many patients with peripheral arterial disease.

Publication Title

Journal of the American Academy of Physician Assistants

Volume

32

Issue

7

First Page

16

Last Page

17

PubMed ID

31241606

Comments

This article was published in Journal of the American Academy of Physician Assistants, Volume 32, Issue 7, pages 16-17.

The published version is available at https://doi.org/10.1097/01.JAA.0000558364.85986.ad.

Copyright © 2019 American Academy of Physician Assistants.

Recommended Citation

Thomas, Rebekah, "Does Rivaroxaban Have a Role in Treating Patients with PAD?" (2019). PCOM Scholarly Works. 2003.
https://digitalcommons.pcom.edu/scholarly_papers/2003